R&D / Scientists

Careers > Teams > Research & Development

Careers > Teams > Research & Development

Research & Development

Research & 
Development

Research & Development

The team

The team

behind our innovations

behind our innovations

If you join our R&D team, you’ll make a real difference to patients by working at the forefront of science and leveraging a broad range of modalities and technologies. Together, we will move our company closer to our vision of a world free of pain.

Get ready to become one of our innovators.

Search results for "". Page 1 of 1, Results 1 to 4 of 4
Title Location Job category Date posted
Senior Analytical Scientist (m/f/d)
Senior Analytical Scientist (m/f/d) Aachen, Germany 12 Oct 2024
Aachen, Germany Research & Development 12 Oct 2024
Head Biochemistry and Structural Biology Lab (m/f/d) Aachen, Germany Research & Development 9 Oct 2024
Automated Purification Scientist (m/f/d)
Automated Purification Scientist (m/f/d) Aachen, Germany 12 Oct 2024
Aachen, Germany Research & Development 12 Oct 2024
(Senior) Scientist Primary Pharmacology of the Target Incubator Unit (f/m/d) Aachen, Germany Research & Development 6 Oct 2024

Our approach to pain R&D

We work at the forefront of pain research in our efforts to create effective pain treatments for patients. We use a wide range of modalities and technologies, including biologics, peptides, small molecules, and cell and gene therapies. We cover every step in the development of an innovative medicine and we strive for excellence in everything we do – from target identification through to commercialisation. We constantly aim to strengthen our research capabilities, and we are always open to collaboration with external partners.

Our team is especially targeting solutions for peripheral neuropathic pain, chronic post-surgical pain, chronic lower back pain, and osteoarthritis. Learn more

Our approach to pain R&D

We work at the forefront of pain research in our efforts to create effective pain treatments for patients. We use a wide range of modalities and technologies, including biologics, peptides, small molecules, and cell and gene therapies. We cover every step in the development of an innovative medicine and we strive for excellence in everything we do – from target identification through to commercialisation. We constantly aim to strengthen our research capabilities, and we are always open to collaboration with external partners. Our team is especially targeting solutions for peripheral neuropathic pain, chronic post-surgical pain, chronic lower back pain, and osteoarthritisLearn More

Our teams and departments within R&D

The experts in our R&D organisation work across specialised teams that join forces to bring innovations forward. Our Research team uses cutting-edge science to ensure strong human validation of our targets and optimisation of our lead structures. The experts in our Development team create leading development strategies for our compounds that lay the basis for a successful market approval.

 

The Portfolio Management & Business Development team maximises the value of our portfolio by driving our projects to success and tapping into the best external innovation opportunities.

Scientists and medical doctors at our Innovation Hub in Boston approach their work with the agility and entrepreneurial mindset you might expect from a small biotech company. Together, they strengthen our company’s access to the latest science by conducting exciting projects and engaging in close collaboration with innovative partners.

Our Drug Safety department puts patients at the centre of everything it does. The team ensures patient safety for Grünenthal’s brands worldwide, and has representatives in all of Grünenthal’s affiliates, as well as at our headquarters in Aachen. They are involved in all phases of a product’s life cycle, and they leverage their deep medical and pharmaceutical expertise, as well as their expert knowledge of international and national guidelines.

Our Regulatory Affairs department brings together passionate, highly skilled and experienced colleagues who are located across countries and regions. They develop fit-for-purpose regulatory strategies that can successfully deliver marketing authorisations for our investigational medicines. This makes it possible for our treatments to make a life-changing positive impact on patients and their families. 

Of course, joining forces is part of our company culture. Our people in R&D work in close collaboration with their Grünenthal colleagues in Commercial and Global Operations, and they are constantly supported by functions like Procurement, Quality Assurance and IT.

Our teams and departments within R&D

The experts in our R&D organisation work across specialised teams that join forces to bring innovations forward. Our Research team uses cutting-edge science to ensure strong human validation of our targets and optimisation of our lead structures. The experts in our Development team create leading development strategies for our compounds that lay the basis for a successful market approval.

The Portfolio Management & Business Development team maximises the value of our portfolio by driving our projects to success and tapping into the best external innovation opportunities.

Scientists and medical doctors at our Innovation Hub in Boston approach their work with the agility and entrepreneurial mindset you might expect from a small biotech company. Together, they strengthen our company’s access to the latest science by conducting exciting projects and engaging in close collaboration with innovative partners.

Our Drug Safety department puts patients at the centre of everything it does. The team ensures patient safety for Grünenthal’s brands worldwide, and has representatives in all of Grünenthal’s affiliates, as well as at our headquarters in Aachen. They are involved in all phases of a product’s life cycle, and they leverage their deep medical and pharmaceutical expertise, as well as their expert knowledge of international and national guidelines.

Our Regulatory Affairs department brings together passionate, highly skilled and experienced colleagues who are located across countries and regions. They develop fit-for-purpose regulatory strategies that can successfully deliver marketing authorisations for our investigational medicines. This makes it possible for our treatments to make a life-changing positive impact on patients and their families. 

Of course, joining forces is part of our company culture. Our people in R&D work in close collaboration with their Grünenthal colleagues in Commercial and Global Operations, and they are constantly supported by functions like Procurement, Quality Assurance and IT.

 

Continuously strengthening our in-house capabilities

We use our scientific expertise to design and conduct studies that open up profound new insights into the pathophysiology of pain. Our Translational Science team develops model systems and biomarkers that bridge the gap between pre-clinical and clinical development to increase the success rate of our research projects. Our Development team delivers efficient and robust manufacturing processes, as well as high-quality clinical development strategies that pave the way for innovative medicines to enter the market and serve patients in need.

Continuously strengthening our in-house capabilities

We use our scientific expertise to design and conduct studies that open up profound new insights into the pathophysiology of pain. Our Translational Science team develops model systems and biomarkers that bridge the gap between pre-clinical and clinical development to increase the success rate of our research projects. Our Development team delivers efficient and robust manufacturing processes, as well as high-quality clinical development strategies that pave the way for innovative medicines to enter the market and serve patients in need.

“Grünenthal is one of the few companies in the pharmaceutical industry that is solely dedicated to innovation in pain research. Our R&D organisation welcomes talented scientists who are enthusiastic about science, patients and our vision of a world free of pain.”

Gillian Burgess

Interim Chief Scientific Officer
 

 

 

“Grünenthal is one of the few companies in the pharmaceutical industry that is solely dedicated to innovation in pain research. Our R&D organisation welcomes talented scientists who are enthusiastic about science, patients and our vision of a world free of pain.”

Gillian Burgess

Interim Chief Scientific Officer

Collaborating with innovative partners

We reinforce our own innovation capabilities by entering into long-term strategic partnerships with leading scientists and institutions around the world. With our Innovation Hub in Boston, we’ve established a centre of excellence for pain research. It invites leading scientists who share our dedicated focus on addressing unmet medical needs in pain to join forces with us to achieve our vision of a world free of pain. Our Innovation Hub features a team of outstanding scientists and medical doctors who initiate and drive innovation projects

independently – from target identification through to clinical Proof of Concept – while also leveraging Grünenthal’s in-house R&D capabilities and collaborating with external partners.

Collaborating with innovative partners

We reinforce our own innovation capabilities by entering into long-term strategic partnerships with leading scientists and institutions around the world. With our Innovation Hub in Boston, we’ve established a centre of excellence for pain research. It invites leading scientists who share our dedicated focus on addressing unmet medical needs in pain to join forces with us to achieve our vision of a world free of pain. Our Innovation Hub features a team of outstanding scientists and medical doctors who initiate and drive innovation projects

independently – from target identification through to clinical Proof of Concept – while also leveraging Grünenthal’s in-house R&D capabilities and collaborating with external partners.

R&D stories lorem ipsum

R&D stories lorem ipsum

Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet. Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet.

Ready to apply?

Why

Why

pain matters

pain matters

1 in 5

or 1.4 billion people worldwide are affected by chronic pain (1)

21

% of chronic pain patients suffer for more than 20 years (2)

78

% of chronic pain patients state that their treatment was not as good as they expected (3)

500

million sick days per year in Europe are caused by musculoskeletal pain alone (4)

60

% of permanent work incapacity in Europe is related to musculoskeletal pain alone (5)

34

billion euros are lost by the European economy due to chronic pain every year (6)

1 in 5

or 1.4 billion people worldwide are
affected by chronic pain (1)

21

% of chronic pain patients suffer for
more than 20 years (2)

78

% of chronic pain patients state
that their treatment was not as
good as they expected (3)

500

million sick days per year in
Europe are caused by musculoskeletal pain
alone (4)

60

% of permanent work incapacity in
Europe is related to musculoskeletal
pain alone (5)

34

billion euros are lost by the
European economy due to chronic
pain every year (6)

(1) Goldberg DS and McGee SJ. Pain as a global public health priority. BMC Public Health. 2011;11:770.
(2) Breivik H et al. Survey of chronic pain in Europe: Prevalence, impact on daily life, and treatment. Eur J Pain. 2006;10:287–333.
(3) Pain Alliance Europe. Survey on Chronic Pain 2017: Diagnosis, Treatment and Impact of Pain. Available at: https://www.pae-eu.eu/wp-content/uploads/2017/12/PAE-Survey-on-Chronic-Pain-June-2017.pdf. Accessed: April 2020.
(4) Wiffen P. Pain: there is a lot of it. Eur J Hosp Pharm. 2013;20:1.
(5) Bevan S et al. Reducing Temporary Work Absence Through Early Intervention: The case of MSDs in the EU. The Work Foundation. 2013
(6) Wiffen P. Pain: there is a lot of it. Eur J Hosp Pharm. 2013;20:1.

Ready to apply?

Ready to apply?